Neogenomics Laboratories

NeoGenomics News

Looking for NeoAccess? Go here to log in



11/29/23

Test Update


Molecular


BCR-ABL1 Non-Standard p230Effective December 11th, this test will be updated to be a Qualitative assay.

  • Results will be reported out as Detected or Not Detected.
  • The analytical sensitivity of the test is 0.1%
  • The result of this test should not be used as the sole criterion for confirming a diagnosis of CML. Correlation with cytogenetic, FISH, and hematologic findings is highly recommended.
  • Monitoring of positive p230 cases can be achieved using this test in combination with the BCR/ABL1/ASS1 t(9;22) FISH assay.

There’ll be no changes in CPT codes and pricing. This update applies only to cases accessioned from Monday, December 11th.


New Test


Introducing! Early-stage NSCLC Panel


The Early-stage NSCLC Panel analyzes 4 actionable and informative early-stage NSCLC biomarkers, EGFR (PCR), ALK (FISH), ROS1 (FISH), PD-L1 22C3 (IHC), relevant for diagnostic evaluation and therapy-selection. This panel is aligned with emerging published clinical trial evidence and the latest clinical testing guidelines, associated with approved targeted therapies. For more info, please contact your local NeoGenomics representative or visit the Early-stage NSCLC webpage.

 

Early-stage non-small cell lung cancer panel

 

Requisition Updates


New versions of the solid tumor test requisitions listed below, aligning with recent test updates, are available for download on our website. For paper copy orders, please contact our Client Services team.

FOLR1 IHC CDx Sponsored Testing Program Request Form ‒ version 110923
Breast Cancer Test Requisition ‒ version 110923

 

Special Announcement


NeoGenomics will be at the San Antonio Breast Cancer Symposium (SABCS)


NeoGenomics is thrilled to be exhibiting at this year's San Antonio Breast Cancer Symposium (SABCS). NeoGenomics leverages its leadership in precision diagnostics to deliver a complete suite of tests that meet the clinical demands for breast cancer patients at any stage.

You will find us at Booth #841. Visit our webpage to schedule a meeting with a NeoGenomics representative to learn more and be sure to register for our product theater featuring RaDaR® MRD.